LeMaitre Vascular entered this earnings season with a reputation for steady, high margin growth. The stock now tells a very different story. Shares closed yesterday at US$105.78 and then reset sharply lower to about US$79, a one day drop of more than 25% as investors reacted to Q2 numbers and guidance.

The headline is not weak profitability. Q2 gross margin reached 72.1% and operating margin came in at 29%, both high for medical devices. The pressure point is a trim to full year revenue growth expectations, which has jarred a market that had priced LeMaitre Vascular for very consistent execution.

Love LeMaitre Vascular's high margins but concerned about how quickly sentiment flipped after the guidance reset? Check out list of solid balance sheet and fundamentals stocks (50 results)

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$70.382 million vs. US$64.232 million (up about 9.6%)
• Net Income, Q2 2026 vs. Q2 2025: US$17.05 million vs. US$13.779 million (up about 23.7%)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.746 vs. US$0.609 (up about 22.5%)
• Gross Margin and Operating Margin, Q2 2026 vs. Q2 2025: Gross margin 72.1% and operating margin 29.0% in Q2 2026 vs. gross margin about 70.0% and operating margin about 27.0% in Q2 2025 (both margins higher year over year)

Tired of scrolling through dense earnings releases and raw figures for LeMaitre Vascular? View a clear visual snapshot of the company's valuation, recent results, and key trends in the company report for LeMaitre Vascular.

LeMaitre bull story: margins and growth under scrutiny

Bulls argue LeMaitre Vascular is a high margin vascular devices company that can compound earnings as pricing, mix and international scale feed through. Q2 results back part of that story. Gross margin reached 72.1% and operating margin 29%, which matches the idea that higher value products like Artegraft and allografts can support rich profitability. Organic revenue rose about 10% with 7% price and 3% units, and 12% organic if you strip out weaker catheters. EMEA and APAC each grew 18%, which supports the push into direct international distribution. Guidance for full year gross margin of about 72.4% and adjusted EPS growth of about 21% also aligns with an operating leverage angle. The hit to revenue guidance and cardiac allograft supply constraints show the growth pathway is not linear and the core margin and product mix milestones are being hit.

Bear case: growth scare, guidance cut and execution risk

Bears argue LeMaitre Vascular carries rich expectations that are vulnerable if growth slows, pricing power fades or execution on new products and markets slips. The 25% share price drop after earnings suggests investors were primed for disappointment and got it through a revenue guidance cut from 12% to 11% organic growth. Q2 missed sales guidance by about US$1.1m and management expects FX, Middle East export issues and cardiac allograft supply constraints to keep biting in the second half. That directly hits the idea of smooth international scaling and reliable supply. Catheters fell 11% after last year’s recall driven stocking, which underlines how one off factors can distort growth. The latest FDA quality observations at the New Jersey plant and a longer than hoped timeline for the Quick Stick indication also support concerns about regulatory and execution risk rather than clearing them.

Compare LeMaitre Vascular's internal margin progress with how the recent 25% share price drop has influenced analyst sentiment. See the consensus price target analysis for LeMaitre Vascular to check where Wall Street thinks NasdaqGM:LMAT goes from here.

Stay Ahead Of Your Next Move

If the sharp reset in LeMaitre Vascular's share price after its guidance update has your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how sentiment evolves. When you decide to take a position, use the Portfolio Command Center to keep your holdings organised and surface only the most important developments that matter to your thesis. For longer term conviction building, plug into the Community to see how other investors are interpreting the same data and events. By spotting potential catalysts and risks early, you give yourself a better chance of staying ahead of the market rather than reacting to it.

Seeking Alternatives Beyond LeMaitre Vascular

Fresh ideas can move quickly. The stocks flying under the radar for now will not stay that way. Scan for quiet momentum before the crowd catches on and act now.

• Spot resilient compounding stories before they hit mainstream screens and review the curated 79 resilient stocks with low risk scores that balance growth potential with tighter risk profiles.
• Chase early breakout themes in automation and manufacturing upgrades by checking the hand picked 36 robotics and automation stocks built around real revenue and clear use cases.
• Position for power grid upgrades while it matters by scanning the focused 37 power grid technology and infrastructure stocks where demand trends and balance sheets already line up.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.